Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 882 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period C Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

NCT02893488
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

NCT03657290
View directory record Official record
Conditions
Healthy
Interventions
vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 4 Interventional

Dose, Effects and Characteristics of Pilocarpine

NCT00803803
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Pilocarpine Concentration, Pilocarpine Frequency
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 1979
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 30, 2026, 6:56 PM EDT
Active, not recruiting Phase 3 Interventional

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

NCT04229979
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine, Observation, GM-CSF, Montanide
Biological · Drug · Other
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Whittier, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04263142
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 Tablet, GSK3640254 Capsule
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons

NCT06162624
View directory record Official record
Conditions
Anxiety, Depression, Depression, Anxiety, Anxiety Disorders
Interventions
Acceptance and Commitment Therapy (ACT), Reflective Journaling
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

AD816 Crossover Study

NCT05793684
View directory record Official record
Conditions
OSA, Obstructive Sleep Apnea
Interventions
Period A, Period B, Period C
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

NCT03613649
View directory record Official record
Conditions
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions
AZD0914, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

NCT01231568
View directory record Official record
Conditions
Cancer
Interventions
Regimen A, Regimen B, Regimen C, Regimen D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Detroit, Michigan • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

NCT03827629
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Treatment A: Naloxone Nasal Spray, Treatment B: Naloxone Nasal Spray, Treatment C: Naloxone HCL Intramuscular (IM) Injection
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits

NCT05523115
View directory record Official record
Conditions
Anxiety, Stress, Memory Deficits, Cortisol Overproduction
Interventions
Heights Smart Supplement
Dietary Supplement
Lead sponsor
Heights
Industry
Eligibility
21 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-227 in Healthy Adults

NCT05818956
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-227
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens

NCT05927753
View directory record Official record
Conditions
Refractive Error - Myopia Bilateral
Interventions
Deseyne Daily Disposable Contact Lens (Test Device)
Device
Lead sponsor
Bruno Vision Care
Industry
Eligibility
18 Years to 40 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Longwood, Florida • Pittsburg, Kansas • Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Evaluation of Regulation Focused Psychotherapy for Children

NCT03594253
View directory record Official record
Conditions
Oppositional Defiant Disorder, Oppositional Defiant Disorder in Children
Interventions
Regulation Focused Psychotherapy for Children
Behavioral
Lead sponsor
Yeshiva University
Other
Eligibility
5 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Spanish Language Homes

NCT05159596
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions
In-Home Technology System, Limited In-Home Technology
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

NCT01656642
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Atezolizumab, Cobimetinib, Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2225 in Healthy Participants (MK-2225-003)

NCT06643390
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
MK-2225, Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Active, not recruiting Not applicable Interventional

Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis

NCT02089880
View directory record Official record
Conditions
Spinal Cord Injuries, Poliomyelitis, Post-polio Syndrome, Arthritis, Lower Motor Neurone Lesion
Interventions
C-brace, Stance control orthosis
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

NCT00274820
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
ascorbic acid, arsenic trioxide, dexamethasone, thalidomide
Dietary Supplement · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

NCT01089062
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, IV Placebo (Saline), Placebo Inhaler, IV Dihydroergotamine Mesylate (DHE)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Not applicable Interventional Results available

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

NCT02598128
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
RELiZORB, Placebo
Device
Lead sponsor
Alcresta Therapeutics, Inc.
Industry
Eligibility
4 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Boise, Idaho • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Emraclidine, Itraconazole, Carbamazepine, Metformin
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

NCT04722887
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 6:56 PM EDT
Active, not recruiting Phase 3 Interventional

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
12
States / cities
Oakland, California • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 6:56 PM EDT